Fig. 3

Pharmacological treatments with CAIs recover expansion capacity of the mutant primary cells isolated from the patient without significantly altered the cell cycle. A Representative flow cytometry histograms for the epidermoid differentiation marker involucrin of KCT or mutant Kmut cells as indicated. Cells were treated with 10 μM brinzolamide (BZA) for 6 days as indicated. B Bar histogram shows percentage of KCT or Kmut involucrin positive cells, as quantified by flow cytometry (n = 2). ns: non-significant. C Clonal expansion capacity of KCT upon 10 μM AZA or RGB 7 days treatments. Cells plated at high density, Kmut double number of cells than KCT, colonies in pink (n = 3 in each essay, four essays, with KCT cells from two different individuals). D Number of cells in C, harvested at confluence of KCT. E cell cycle analyses of cells in D, as determined by DNA content stained with Propidium Iodide. *p < 0.05, **p < 0.01